AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1550521 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone and 1 g metronidazole
Number of subjects: 280
Study 1550521 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone
Number of subjects: 280
Study 1550521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin and 1 g metronidazole
Number of subjects: 280
Study 1550521 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 280
Study 3084176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide
Number of subjects: 0
Study 30649613 — intervention group
Group type: EXPERIMENTAL
Intervention: CD HORIZON BalanC rod
Number of subjects: 56
Study 30649613 — intervention group
Group type: EXPERIMENTAL
Intervention: S4 Dynamic rod
Number of subjects: 56
Study 30943550 — intervention group
Group type: EXPERIMENTAL
Intervention: TTA Rapid
Number of subjects: 26
Study 30943550 — intervention group
Group type: COMPARATOR
Intervention: TPLO
Number of subjects: 26
Study 28885365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation plus EMG-biofeedback therapy
Number of subjects: 103
Study 28885365 — intervention group
Group type: COMPARATOR
Intervention: Swallowing function training (Control)
Number of subjects: 103
Study 25005717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (IPT) with 12 h on and 12 h off cycles
Number of subjects: 75
Study 25005717 — intervention group
Group type: COMPARATOR
Intervention: Continuous phototherapy (CPT)
Number of subjects: 75
Study 23266209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA (100 mg/kg/day for the first month and 1g per day thereafter for 12 months)
Number of subjects: 41
Study 23266209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (germ oil)
Number of subjects: 41
Study 23266209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA
Number of subjects: 41
Study 23266209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21847583 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL from obese metabolic syndrome patients
Number of subjects: 30
Study 21847583 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL from type 2 diabetic patients
Number of subjects: 30
Study 21847583 — intervention group
Group type: COMPARATOR
Intervention: Control LDL from volunteers
Number of subjects: 30
Study 19548163 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed gum (5 g) incorporated in wheat flour chapattis, consumed daily for 3 months.
Number of subjects: 60
Study 19548163 — intervention group
Group type: COMPARATOR
Intervention: Control group consumed identical diet without flaxseed gum.
Number of subjects: 60
Study 16680932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride (60 mg) pretreatment 2 hours before immunization injection
Number of subjects: 134
Study 16680932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 134
Study 15571443 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent voucher ($100)
Number of subjects: 211
Study 15571443 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent voucher ($100)
Number of subjects: 211
Study 15571443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 11681649 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaszczak's method
Number of subjects: 4
Study 11681649 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of dynamic sequences (FADS)
Number of subjects: 4
Study 11681649 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform attenuation correction (UAC)
Number of subjects: 4
Study 11681649 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-beam attenuation correction
Number of subjects: 4
Study 11681649 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-beam inhomogeneous tissue attenuation correction
Number of subjects: 4
Study 9644285 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory requirement (remembering the precue)
Number of subjects: 0
Study 9644285 — intervention group
Group type: COMPARATOR
Intervention: Continually available precue
Number of subjects: 0
Study 8169755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose RSV immune globulin (750 mg/kg, 15 ml/kg)
Number of subjects: 249
Study 8169755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RSV immune globulin (150 mg/kg, 3 ml/kg)
Number of subjects: 249
Study 8169755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RSVIG)
Number of subjects: 249
Study 8169755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose RSV immune globulin
Number of subjects: 249
Study 3275861 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/d)
Number of subjects: 7
Study 3275861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg lactose/d)
Number of subjects: 7
Study 3275861 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (15 mg/d)
Number of subjects: 7
Study 29064335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 2200
Study 29064335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2200
Study 27322354 — intervention group
Group type: EXPERIMENTAL
Intervention: QIVc
Number of subjects: 2680
Study 27322354 — intervention group
Group type: COMPARATOR
Intervention: TIV1c
Number of subjects: 2680
Study 27322354 — intervention group
Group type: COMPARATOR
Intervention: TIV2c
Number of subjects: 2680
Study 24287166 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 32
Study 24287166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23224510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 10 mg
Number of subjects: 50
Study 23224510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 20 mg
Number of subjects: 50
Study 23224510 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg
Number of subjects: 50
Study 23224510 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)-tetrahydrocannabinol (THC) 15 mg
Number of subjects: 50
Study 23224510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22078433 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN transcatheter heart valve
Number of subjects: 36
Study 19380451 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 139
Study 19380451 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 139
Study 19380451 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus Zoledronic acid
Number of subjects: 139
Study 16300823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene program including educational program and environmental changes
Number of subjects: 1029
Study 16300823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1029
Study 15157730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 88 microg via metered-dose inhaler and Aerochamber, twice daily for 2 years
Number of subjects: 0
Study 15157730 — intervention group
Group type: COMPARATOR
Intervention: Placebo via metered-dose inhaler and Aerochamber, twice daily for 2 years
Number of subjects: 0
Study 15157730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 88 microg
Number of subjects: 0
Study 15157730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12174401 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention program
Number of subjects: 0
Study 12174401 — intervention group
Group type: COMPARATOR
Intervention: Control county (not specified)
Number of subjects: 0
Study 9028537 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (hGH) treatment
Number of subjects: 18
Study 8503339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 90 mg/day
Number of subjects: 165
Study 8503339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 375 mg/day
Number of subjects: 165
Study 8503339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 750 mg/day
Number of subjects: 165
Study 8503339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 375 mg/day (hormone-treated patients)
Number of subjects: 165
Study 8503339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 750 mg/day (hormone-treated patients)
Number of subjects: 165
Study 8503339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (all doses)
Number of subjects: 165
Study 3067610 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of L-carnitine by intravenous infusion
Number of subjects: 15
Study 3067610 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g/kg of ethanol in the form of white wine
Number of subjects: 15
Study 3067610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol plus carnitine
Number of subjects: 15
Study 3067610 — intervention group
Group type: COMPARATOR
Intervention: L-carnitine alone
Number of subjects: 15
Study 29898710 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for alleviation of postoperative vomiting in children
Number of subjects: 282
Study 29898710 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental expectancy
Number of subjects: 282
Study 29898710 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental anxiety
Number of subjects: 282
Study 26567593 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaferon (ultra-high dilutions of antibodies to human interferon γ), n=20
Number of subjects: 40
Study 26567593 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=20
Number of subjects: 40
Study 25623388 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling and SMS reminders
Number of subjects: 150
Study 25623388 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 150
Study 22888817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental contrasting
Number of subjects: 467
Study 16542795 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy radiation therapy (RT)
Number of subjects: 3706
Study 16542795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy radiation therapy (RT)
Number of subjects: 3706
Study 16542795 — intervention group
Group type: COMPARATOR
Intervention: No flank radiation therapy (RT)
Number of subjects: 3706
Study 16542795 — intervention group
Group type: EXPERIMENTAL
Intervention: NWTS-4
Number of subjects: 3706
Study 12677011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial pro-urokinase (r-proUK) treatment
Number of subjects: 0
Study 12677011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10626776 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery Asberg Depression Rating Scale (MADRS)
Number of subjects: 512
Study 10626776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Anxiety Rating Scale (HAM-A)
Number of subjects: 512
Study 10626776 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms observed
Number of subjects: 512
Study 10626776 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms in subjects with fewer than five symptoms
Number of subjects: 512
Study 8610768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (transdermal or oral)
Number of subjects: 32
Study 2277578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% plain marcaine 10 mL to each side (Group B)
Number of subjects: 36
Study 2277578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% plain marcaine with 1:200000 epinephrine 10 mL to each side (Group C)
Number of subjects: 36
Study 2277578 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 36
Study 531512 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 8
Study 531512 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 8
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: PCWP ≤ 8 mmHg
Number of subjects: 743
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 < PCWP ≤ 11 mmHg
Number of subjects: 743
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: PCWP > 11 mmHg
Number of subjects: 743
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: PCWP (per mmHg)
Number of subjects: 743
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (per year)
Number of subjects: 743
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Caucasian race
Number of subjects: 743
Study 28400191 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PVR (per Woods Unit)
Number of subjects: 743
Study 25581426 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover (40 mg dried leaves, 2 capsules daily for 12 weeks)
Number of subjects: 72
Study 25581426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 mg starch, 2 capsules daily for 12 weeks)
Number of subjects: 72
Study 22959576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg before surgical incision and 15 mg/kg after protamine neutralization)
Number of subjects: 120
Study 22959576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 120
Study 22959576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 120
Study 22959576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20965463 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1548
Study 20965463 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1548
Study 18782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA; Copaxone)
Number of subjects: 0
Study 18782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNB)
Number of subjects: 0
Study 18782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Various disease-modifying therapies (DMTs)
Number of subjects: 0
Study 15741722 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-supervised toothbrushing once a day at school with 1,450 ppm fluoride toothpaste
Number of subjects: 517
Study 15741722 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 517
Study 15741722 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-supervised toothbrushing
Number of subjects: 517
Study 12182252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally every 12 hours with IV rosiglitazone 2 mg
Number of subjects: 12
Study 12182252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally every 12 hours with oral rosiglitazone 4 mg
Number of subjects: 12
Study 12182252 — intervention group
Group type: COMPARATOR
Intervention: IV rosiglitazone 2 mg alone
Number of subjects: 12
Study 12182252 — intervention group
Group type: COMPARATOR
Intervention: Oral rosiglitazone 4 mg alone
Number of subjects: 12
Study 10416484 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 0
Study 10416484 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 8562272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (calcium-antagonist)
Number of subjects: 1000
Study 8562272 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 1000
Study 1775608 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine at 300 mg daily
Number of subjects: 94
Study 1775608 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine at 150 mg daily
Number of subjects: 94
Study 1775608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 6456165 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy program, three times a week for nine weeks
Number of subjects: 20
Study 6456165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 31318750 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (635 nm, 15 mW) with standard treatment (rest, icing, compression, elevation)
Number of subjects: 19
Study 31318750 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (rest, icing, compression, elevation)
Number of subjects: 19
Study 28651971 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messaging intervention focusing on anticipated regret and self-monitoring of PMC
Number of subjects: 124
Study 28651971 — intervention group
Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 124
Study 26299751 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (BAL) group, 4 weeks indoor and 4 weeks outdoor balance training, 2-hour sessions per week
Number of subjects: 70
Study 26299751 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group, 8 weeks upper limb training, same dosage as BAL group
Number of subjects: 70
Study 26299751 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (BAL) group
Number of subjects: 70
Study 23718743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (Voluven™) 10 mL/kg
Number of subjects: 10
Study 23718743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate 20 mL/kg
Number of subjects: 10
Study 23718743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyethyl starch followed by Ringer's acetate
Number of subjects: 10
Study 22580730 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG in the highest quintile
Number of subjects: 806
Study 19454549 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg oral nicotine pouch (Zonnic pouch)
Number of subjects: 30
Study 19454549 — intervention group
Group type: COMPARATOR
Intervention: Nicotine chewing gum
Number of subjects: 30
Study 19454549 — intervention group
Group type: COMPARATOR
Intervention: Placebo pouch
Number of subjects: 30
Study 17826318 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (400 mug rapid bolus)
Number of subjects: 784
Study 17826318 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 784
Study 17826318 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 784
Study 15511297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 0
Study 11463108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular arteether (3.2 mg/kg on Day 0, followed by 1.6 mg/kg on Days 1 to 4)
Number of subjects: 102
Study 11463108 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine dihydrochloride (20 mg of the salt/kg, followed by 10 mg of the salt/kg every 8 hr up to Day 6)
Number of subjects: 102
Study 11463108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular arteether
Number of subjects: 102
Study 11463108 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine dihydrochloride
Number of subjects: 102
Study 9589523 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cranking aerobic training program (30 min/session, three times/week, 6 weeks)
Number of subjects: 12
Study 9589523 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study 8024164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1,200 mg/day)
Number of subjects: 45
Study 8024164 — intervention group
Group type: COMPARATOR
Intervention: Buflomedil (600 mg/day)
Number of subjects: 45
Study 8024164 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (60 mg/day)
Number of subjects: 45
Study 2521297 — intervention group
Group type: EXPERIMENTAL
Intervention: Brequinar sodium (various schedules: short-term IV infusion every 3 weeks, weekly, twice weekly, five times daily every 4 weeks)
Number of subjects: 0
Study 2521297 — intervention group
Group type: EXPERIMENTAL
Intervention: Brequinar sodium (highest dose levels)
Number of subjects: 0
Study 2521297 — intervention group
Group type: EXPERIMENTAL
Intervention: Brequinar sodium
Number of subjects: 0
Study 174388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.5 g/kg)
Number of subjects: 9
Study 174388 — intervention group
Group type: COMPARATOR
Intervention: Control (beverage alone)
Number of subjects: 9
Study 31384903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid flaps
Number of subjects: 58
Study 31384903 — intervention group
Group type: COMPARATOR
Intervention: Free flaps
Number of subjects: 58
Study 31384903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 28958678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiviral therapy (oseltamivir 75 mg, amantadine 100 mg, ribavirin 600 mg)
Number of subjects: 633
Study 28958678 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir monotherapy
Number of subjects: 633
Study 28958678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiviral therapy
Number of subjects: 633
Study 26401478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic endoscopy and bimanual-binarial dissection (group C)
Number of subjects: 0
Study 26401478 — intervention group
Group type: COMPARATOR
Intervention: Binarial two-hands dissection using an endoscope holder (group A)
Number of subjects: 0
Study 26401478 — intervention group
Group type: COMPARATOR
Intervention: Combined binarial two- and three-handed dissection with one surgeon guiding the endoscope (group B)
Number of subjects: 0
Study 24245700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized fibular flap
Number of subjects: 25
Study 24245700 — intervention group
Group type: COMPARATOR
Intervention: Soft tissue free flap
Number of subjects: 25
Study 21194496 — intervention group
Group type: EXPERIMENTAL
Intervention: ALGOS algorithm (case management algorithm)
Number of subjects: 0
Study 21194496 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic telephone contact
Number of subjects: 0
Study 21194496 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis card
Number of subjects: 0
Study 21194496 — intervention group
Group type: EXPERIMENTAL
Intervention: Short letters or postcards
Number of subjects: 0
Study 18337052 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 150
Study 18337052 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 150